Pfizer Chief Medical Officer Freda Lewis-Hall has been a proponent of the need for cooperation among pharmaceutical and biotechnology companies, government agencies and academic institutions. Pfizer's drug, Kalydeco, approved in January 2012, is the first drug that targets the underlying cause of cystic fibrosis, and was developed in concert with the Cystic Fibrosis Foundation. Development of Kalydeco was just one medical research achievement highlighted during FasterCures' Celebration of Science event in Washington.